Navigation Links
Diatos Announces Positive Clinical Results for its DTS-201,Doxorubicin Prodrug Program

PARIS--(BUSINESS WIRE)--Jun 4, 2007 - Diatos SA, an international biopharmaceutical company focusing on the research, development and commercialization of targeted anti-cancer drugs, today announced that they presented data from a Phase I clinical trial of their anti-cancer compound, DTS-201, at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA.

DTS-201 is a doxorubicin prodrug developed for the targeted treatment of several solid cancers, including chemo-resistant tumors. The product is activated by enzymes specific to the tumor environment. During its Phase I clinical trial, DTS-201 was shown to be well tolerated and able to deliver high doses of free doxorubicin in humans.

The purpose of the DTS-201 Phase I clinical study is to assess the product's Maximum Tolerated Dose (MTD), safety profile and pharmacokinetic profile in patients with advanced or metastatic solid tumors. In a poster presentation entitled "Results of a Phase I study of DTS-201, a peptidic prodrug of doxorubicin in patients with solid tumors (Abstract # 2547)", researchers concluded that:

-- DTS-201 was well tolerated by twenty-five cancer patients treated with doses of up to 400 mg/m2 every three weeks. This corresponds to 3.75 times the standard dose of doxorubicin;

-- DTS-201 was safe and well tolerated at cumulative doses of up to 2750 mg/m2;

-- Evidence of clinical efficacy was observed: two patients showed partial responses and three patients with chemo-resistant tumors showed disease stabilisation;

-- The recommended dose for Phase II clinical trials is 400 mg/m2.

The high levels of tolerance to the product and positive clinical responses observed during this Phase I trial strongly support an assessment of the efficacy of DTS-201 in a Phase II study.

"DTS-201 is a safe and active compound which allowed delivery of a high dose of doxorubicin with
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:3/27/2015)... , March 27, 2015   Hospira, ... leader in biosimilars and the world,s leading provider ... studies that support an evaluation of biosimilarity of ... Food and Drug Administration (FDA) conditionally approved name ... EPOGEN™ (epoetin alfa). These study data were presented ...
(Date:3/27/2015)... , March 27, 2015  Delcath Systems, ... and medical device company focused on oncology with ... metastatic liver cancers, announces the reporting of data ... Melphalan Hydrochloride for Injection with the Delcath Hepatic ... poster presentation at the Society of Surgical Oncology ...
(Date:3/26/2015)... WOODBRIDGE, ON , March 26, 2015 /PRNewswire/ - Pivotal ... specialty pharmaceutical company with a focus on Omega-3 therapies ... March 25, 2015 it issued 763,752 common shares of ... payment of interest for the period of December 5 ... on its outstanding Convertible Notes that is due on ...
Breaking Medicine Technology:Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
... 16, 2011 DecisionView Inc., a leading provider ... for life sciences companies, today announced that a ... Roche have agreed to participate in the creation ... based on real-world clinical performance data. Each of ...
... N.J., June 16, 2011 Ferring Pharmaceuticals Inc. proudly ... Houston in an effort to help increase awareness about ... of healthy aging. The NSG is ... and is organized by the National Senior Games Association, ...
Cached Medicine Technology:DecisionView to Create Clinical Trial Enrollment Benchmarks 2DecisionView to Create Clinical Trial Enrollment Benchmarks 3Ferring Pharmaceuticals Inc. Congratulates All 2011 Summer National Senior Games Athletes 2Ferring Pharmaceuticals Inc. Congratulates All 2011 Summer National Senior Games Athletes 3Ferring Pharmaceuticals Inc. Congratulates All 2011 Summer National Senior Games Athletes 4
(Date:3/29/2015)... North American Seminars receives Texas Board Physical ... Courses . , Utilizing Pilates to Enhance ... approval # 56399TX      , The Interactive Shoulder ... - 10.5 hours - Texas Board of Physical Therapy ... of the SI Joint - 10 hours - Texas ...
(Date:3/28/2015)... Tucson, AZ. (PRWEB) March 28, 2015 ... according to a new study by researchers ... (HSPH). , Produced with the support of the Coffee ... the journal Molecular Psychiatry this past fall, the study—one ... a meta-analysis of genomic data from more than 120,000 ...
(Date:3/28/2015)... York, New York (PRWEB) March 28, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) involving devices manufactured by C.R. Bard, ... litigation underway in U.S. District Court, Southern District ... S. Grand, is serving on the Plaintiffs’ Steering ... 24th, the Court has granted certain defendants named ...
(Date:3/28/2015)... 2015 An article in Fortune on ... prove critical to organizations that deal with PCI (Payment ... of data security, is worsening . Using numbers ... every major category out of the twelve measured improved, ... all the craziness that has gone on in the ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... injuries is a growing field in orthopaedic medicine. While ... labral tear to confirm the pain etiology, research presented ... ( AOSSM ) Specialty Day suggests that pain relief ... following arthroscopic hip surgery. , “Our study looked ...
Breaking Medicine News(10 mins):Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2
... Streamline Health Solutions, Inc. (Nasdaq: STRM ) today announced the financial ... , , Highlights of the quarter and the nine-month ... Revenues increased 11% versus comparable quarter in the previous year; , ... , Year-to-date company has won 8 total new ...
... role in immune, inflammatory processes, study says , , ... have higher levels of the obesity-related hormone leptin than ... study included 77 psoriasis patients and a control group ... researchers gathered health information about the participants and analyzed ...
... Dec. 15 Following is a statement from Michael ... in regards to its financial exposure with Madoff Securities: ... Health System,s financial exposure with Madoff Securities is limited to ... who stipulated that the funds be invested with Madoff. The ...
... footwear choices, properly moisturizing can soothe holiday soles. , ... Bethesda, MD ... an extra boost of holiday cheer, the same winter weather that puts ... fierce toll on their feet. , , , , ,“Foot ailments ...
... for delivering,albuterol, a fast-acting bronchial dilator, currently use propellants ... beginning December 31st,2009, or replacement HFA,s. Both propellants are ... at near-supersonic speeds. , ... stream of air by ejecting,the medication from a microfluidic ...
... of all Californians under age 65 were without health insurance ... brief released today by the UCLA Center for Health Policy ... data from the California Health Interview Survey (CHIS), the policy ... insurance coverage for all or some of 2007, the most ...
Cached Medicine News:Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 2Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 3Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 4Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 5Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 6Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 7Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 8Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 9Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 10Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 11Health News:Obesity-Related Hormone Tied to Psoriasis 2Health News:North Shore-LIJ Health System Exposure With Madoff Securities Limited to $5.7M 2Health News:‘Tis The Season to Avoid Foot Follies: Tips to Keep You on Your Feet 2Health News:Next Safety Develops an Air-Based Asthma Medication Inhaler That Does Not Use a Refrigerant Propellant 2Health News:Next Safety Develops an Air-Based Asthma Medication Inhaler That Does Not Use a Refrigerant Propellant 3Health News:Nearly 6.4 million Californians lack health insurance, report shows 2
... Photosilk Plus offers a new and efficient ... medicine treatments. Springing from ongoing research and ... is not just a light source, but ... Photosilk Plus represents new horizons in pulsed-light-based ...
Auto Refkeratomoeter...
The convenience of safe and precise Patient Controlled Analgesia in a flexible system designed with advanced technology. This is progressive, innovative, and effective pain management in a sophistica...
Pain management can be complicated. But that doesn't mean your PCA infusion system should be. The new SYNDEO PCA Syringe Pump streamlines pain therapy with a powerful combination of intelligent desig...
Medicine Products: